Jonathan Powlson
Oxford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
Journal: The Lancet. Microbe
Published: October 05, 2023
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
Journal: The Lancet. Microbe
Published: October 05, 2023
Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine.
Journal: Vaccines
Published: March 11, 2019
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal.
Journal: The Journal of infectious diseases
Published: July 02, 2018
Activation-induced Markers Detect Vaccine-Specific CD4⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials.
Journal: Vaccines
Published: June 25, 2018
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP.
Journal: NPJ vaccines
Published: October 05, 2017
Prime and target immunization protects against liver-stage malaria in mice.
Journal: Science translational medicine
Published: September 08, 2017
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.
Journal: The New England journal of medicine
Published: January 29, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026